

Neurofibromatoses Type I (Von Recklinghausen's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N656C4EB740BEN.html>

Date: November 2022

Pages: 72

Price: US\$ 2,000.00 (Single User License)

ID: N656C4EB740BEN

Abstracts

Neurofibromatoses Type I (Von Recklinghausen's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Drugs In Development, 2022, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders),

complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 5 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neurofibromatosis Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neurofibromatosis Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatosis Type I (Von Recklinghausen's Disease) (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neurofibromatosis Type I (Von Recklinghausen's Disease) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neurofibromatosis Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Overview

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Companies Involved in

Therapeutics Development

Advenchen Laboratories LLC

Alexion Pharmaceuticals Inc

AstraZeneca Plc

Binjiang Pharma, Inc.

Bristol-Myers Squibb Co

Eli Lilly and Co

Fochon Pharmaceutical Ltd

Healx Ltd

Mulberry Biotherapeutics Inc

NFlection Therapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Pasithea Therapeutics Corp

Pfizer Inc

Sino Biopharmaceutical Ltd

SpringWorks Therapeutics Inc

Vyriad Inc

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action
AL-2846 - Drug Profile
Product Description
Mechanism Of Action
ALXN-1910 - Drug Profile
Product Description
Mechanism Of Action
binimetinib - Drug Profile
Product Description
Mechanism Of Action
CIP-137401 - Drug Profile
Product Description
Mechanism Of Action
FCN-159 - Drug Profile
Product Description
Mechanism Of Action
HL-085 - Drug Profile
Product Description
Mechanism Of Action
ipilimumab - Drug Profile
Product Description
Mechanism Of Action
mirdametinib - Drug Profile
Product Description
Mechanism Of Action
MUL-001 - Drug Profile
Product Description
Mechanism Of Action
Neurofibromatosis type 1 cutaneous neurofibroma (cNF) - Drug Profile
Product Description
Mechanism Of Action
Neurofibromatosis type 1 plexiform neurofibroma (pNF) - Drug Profile
Product Description
Mechanism Of Action
NFX-179 - Drug Profile
Product Description
Mechanism Of Action
nivolumab - Drug Profile
Product Description

Mechanism Of Action

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile

Product Description

Mechanism Of Action

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Neurofibromatoses Type I - Drug Profile

Product Description

Mechanism Of Action

TQB-3234 - Drug Profile

Product Description

Mechanism Of Action

trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

Treatment for Neurofibromatosis Type 1 - Drug Profile

Product Description

Mechanism Of Action

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Dormant Projects

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Product Development
Milestones

Featured News & Press Releases

Sep 27, 2022: Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type

Nov 29, 2021: SpringWorks Therapeutics announces full enrollment of Phase 2b ReNeu trial evaluating Mirdametininib in adult and pediatric patients with NF1-associated plexiform neurofibromas

Sep 27, 2021: AstraZeneca Pharma India gets DCGI nod to import, market Selumetinib

Aug 18, 2021: NFlection Therapeutics announces Orphan Drug Designation of NFX-179 for the treatment of cutaneous neurofibromatosis type

Jul 20, 2021: SpringWorks Therapeutics announces issuance of new U.S composition of matter patent to polymorphic form of mirdametininib, extending patent protection into 2041

Jun 22, 2021: Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas

May 31, 2021: AZ's Koselugo scores regulatory nod for children with rare neurofibroma

May 26, 2021: NFlection Therapeutics' NFX-179 gel demonstrates safety and significant reduction in p-ERK, a key biomarker driving neurofibroma tumor growth, in positive data

from a 28-day phase 2a clinical trial

Feb 25, 2021: SpringWorks Therapeutics reports interim data from phase 2b ReNeu trial of Mirdametinib for patients with NF1-PN and provides trial update

Jun 30, 2020: Selumetinib granted orphan drug designation in Japan for neurofibromatosis type

Apr 14, 2020: KOSELUGO (selumetinib) approved for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas in pediatric patients, available from Onco360

Apr 13, 2020: FDA approves AstraZeneca's Koselugo to treat rare genetic disorder

Apr 10, 2020: FDA Approves First Ever Treatment for Neurofibromatosis

Mar 18, 2020: In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

Nov 15, 2019: FDA grants priority review to tumour drug selumetinib

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen's Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Advenchen Laboratories LLC, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Alexion Pharmaceuticals Inc, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by AstraZeneca Plc, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Binjiang Pharma, Inc., 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Bristol-Myers Squibb Co, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Eli Lilly and Co, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Fochon Pharmaceutical Ltd, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Healx Ltd, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Mulberry Biotherapeutics Inc, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by NFlection Therapeutics Inc, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Novartis AG, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Ono Pharmaceutical Co Ltd, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Pasithea Therapeutics Corp, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Pfizer Inc, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Sino Biopharmaceutical Ltd, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by SpringWorks Therapeutics Inc, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Vyriad Inc, 2022

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen's Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Neurofibromatoses Type I (Von Recklinghausen's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N656C4EB740BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N656C4EB740BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

